95 related articles for article (PubMed ID: 28972876)
1. miR-200b regulates epithelial-mesenchymal transition of chemo-resistant breast cancer cells by targeting FN1.
Yang X; Hu Q; Hu LX; Lin XR; Liu JQ; Lin X; Dinglin XX; Zeng JY; Hu H; Luo ML; Yao HR
Discov Med; 2017 Sep; 24(131):75-85. PubMed ID: 28972876
[TBL] [Abstract][Full Text] [Related]
2. Reduced expression of miR-200 family members contributes to antiestrogen resistance in LY2 human breast cancer cells.
Manavalan TT; Teng Y; Litchfield LM; Muluhngwi P; Al-Rayyan N; Klinge CM
PLoS One; 2013; 8(4):e62334. PubMed ID: 23626803
[TBL] [Abstract][Full Text] [Related]
3. miR-200b as a prognostic factor in breast cancer targets multiple members of RAB family.
Ye F; Tang H; Liu Q; Xie X; Wu M; Liu X; Chen B; Xie X
J Transl Med; 2014 Jan; 12():17. PubMed ID: 24447584
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-708-3p mediates metastasis and chemoresistance through inhibition of epithelial-to-mesenchymal transition in breast cancer.
Lee JW; Guan W; Han S; Hong DK; Kim LS; Kim H
Cancer Sci; 2018 May; 109(5):1404-1413. PubMed ID: 29575368
[TBL] [Abstract][Full Text] [Related]
5. Suppression of poised oncogenes by ZMYND8 promotes chemo-sensitization.
Mukherjee S; Adhikary S; Gadad SS; Mondal P; Sen S; Choudhari R; Singh V; Adhikari S; Mandal P; Chaudhuri S; Sengupta A; Lakshmanaswamy R; Chakrabarti P; Roy S; Das C
Cell Death Dis; 2020 Dec; 11(12):1073. PubMed ID: 33323928
[TBL] [Abstract][Full Text] [Related]
6. microRNA-29 negatively regulates EMT regulator N-myc interactor in breast cancer.
Rostas JW; Pruitt HC; Metge BJ; Mitra A; Bailey SK; Bae S; Singh KP; Devine DJ; Dyess DL; Richards WO; Tucker JA; Shevde LA; Samant RS
Mol Cancer; 2014 Aug; 13():200. PubMed ID: 25174825
[TBL] [Abstract][Full Text] [Related]
7. ZRANB2 and SYF2-mediated splicing programs converging on ECT2 are involved in breast cancer cell resistance to doxorubicin.
Tanaka I; Chakraborty A; Saulnier O; Benoit-Pilven C; Vacher S; Labiod D; Lam EWF; Bièche I; Delattre O; Pouzoulet F; Auboeuf D; Vagner S; Dutertre M
Nucleic Acids Res; 2020 Mar; 48(5):2676-2693. PubMed ID: 31943118
[TBL] [Abstract][Full Text] [Related]
8. The N-terminal polypeptide derived from viral macrophage inflammatory protein II reverses breast cancer epithelial-to-mesenchymal transition via a PDGFRα-dependent mechanism.
Yang QL; Zhang LY; Wang HF; Li Y; Wang YY; Chen TT; Dai MF; Wu HH; Chen SL; Wang WR; Wu Q; Chen CJ; Zhou CZ
Oncotarget; 2017 Jun; 8(23):37448-37463. PubMed ID: 28415580
[TBL] [Abstract][Full Text] [Related]
9. miR-200b restrains EMT and aggressiveness and regulates matrix composition depending on ER status and signaling in mammary cancer.
Piperigkou Z; Franchi M; Riethmüller C; Götte M; Karamanos NK
Matrix Biol Plus; 2020 May; 6-7():100024. PubMed ID: 33543022
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-200b-mediated reversion of a spectrum of epithelial-to-mesenchymal transition states in recessive dystrophic epidermolysis bullosa squamous cell carcinomas.
Illmer J; Zauner R; Piñón Hofbauer J; Wimmer M; Gruner S; Ablinger M; Bischof J; Dorfer S; Hainzl S; Tober V; Bergson S; Sarig O; Samuelov L; Guttmann-Gruber C; Shalom-Feuerstein R; Sprecher E; Koller U; Laimer M; Bauer JW; Wally V
Br J Dermatol; 2023 Dec; 190(1):80-93. PubMed ID: 37681509
[TBL] [Abstract][Full Text] [Related]
11. Ceramide synthase 4 overexpression exerts oncogenic properties in breast cancer.
Kim SJ; Seo I; Kim MH; Park JW; Kim S; Park WJ
Lipids Health Dis; 2023 Oct; 22(1):183. PubMed ID: 37885013
[TBL] [Abstract][Full Text] [Related]
12. Does insulin make breast cancer cells resistant to doxorubicin toxicity?
Lykhova O; Zavelevich M; Philchenkov A; Vidasov N; Kozak T; Lozovska Y; Andrusyshyna I; Bishayee A; Borikun T; Lukianova N; Chekhun V
Naunyn Schmiedebergs Arch Pharmacol; 2023 Nov; 396(11):3111-3122. PubMed ID: 37231169
[TBL] [Abstract][Full Text] [Related]
13. Melatonin and Its Role in the Epithelial-to-Mesenchymal Transition (EMT) in Cancer.
Martínez-Campa C; Álvarez-García V; Alonso-González C; González A; Cos S
Cancers (Basel); 2024 Feb; 16(5):. PubMed ID: 38473317
[TBL] [Abstract][Full Text] [Related]
14. Identification of distinct miRNA target regulation between breast cancer molecular subtypes using AGO2-PAR-CLIP and patient datasets.
Farazi TA; Ten Hoeve JJ; Brown M; Mihailovic A; Horlings HM; van de Vijver MJ; Tuschl T; Wessels LF
Genome Biol; 2014 Jan; 15(1):R9. PubMed ID: 24398324
[TBL] [Abstract][Full Text] [Related]
15. miR-200c sensitizes breast cancer cells to doxorubicin treatment by decreasing TrkB and Bmi1 expression.
Kopp F; Oak PS; Wagner E; Roidl A
PLoS One; 2012; 7(11):e50469. PubMed ID: 23209748
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-200b regulates distal airway development by maintaining epithelial integrity.
Khoshgoo N; Visser R; Falk L; Day CA; Ameis D; Iwasiow BM; Zhu F; Öztürk A; Basu S; Pind M; Fresnosa A; Jackson M; Siragam VK; Stelmack G; Hicks GG; Halayko AJ; Keijzer R
Sci Rep; 2017 Jul; 7(1):6382. PubMed ID: 28743913
[TBL] [Abstract][Full Text] [Related]
17. Promising applications of nanotechnology in inhibiting chemo-resistance in solid tumors by targeting epithelial-mesenchymal transition (EMT).
Tangsiri M; Hheidari A; Liaghat M; Razlansari M; Ebrahimi N; Akbari A; Varnosfaderani SMN; Maleki-Sheikhabadi F; Norouzi A; Bakhtiyari M; Zalpoor H; Nabi-Afjadi M; Rahdar A
Biomed Pharmacother; 2024 Jan; 170():115973. PubMed ID: 38064969
[TBL] [Abstract][Full Text] [Related]
18. Network analysis of EMT and MET micro-RNA regulation in breast cancer.
Drago-García D; Espinal-Enríquez J; Hernández-Lemus E
Sci Rep; 2017 Oct; 7(1):13534. PubMed ID: 29051564
[TBL] [Abstract][Full Text] [Related]
19. CADM1 impairs the effect of miR-1246 on promoting cell cycle progression in chemo-resistant leukemia cells.
Xie B; Zhao L; Zhang Z; Zhou C; Tian Y; Kang Y; Chen J; Wei H; Li L
BMC Cancer; 2023 Oct; 23(1):955. PubMed ID: 37814227
[TBL] [Abstract][Full Text] [Related]
20. Synergistic reversal effect of epithelial-to-mesenchymal transition by miR-223 inhibitor and genistein in gemcitabine-resistant pancreatic cancer cells.
Ma J; Zeng F; Ma C; Pang H; Fang B; Lian C; Yin B; Zhang X; Wang Z; Xia J
Am J Cancer Res; 2016; 6(6):1384-95. PubMed ID: 27429851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
